Desoximetasone
Based on 1 publication(s) in Google Scholar
Desoximetasone is a corticosteroid and a substrate of cytochrome P450 3A4. Desoximetasone has anti-inflammatory, anti-allergic, and immunosuppressive effects. Desoximetasone can be used in the research of various skin diseases, such as skin allergies, atopic dermatitis, and psoriasis.
For research use only. We do not sell to patients.
- Purity: 98.72%
- CAS No.: 382-67-2
- Formula: C22H29FO4
- Molecular Weight:376.46
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
Immunology/Inflammation Compound Library
HY-L007
-
Metabolism/Protease Compound Library
HY-L012
-
FDA-Approved Drug Library
HY-L022
-
Anti-Aging Compound Library
HY-L034
-
Drug Repurposing Compound Library
HY-L035
-
Antioxidant Compound Library
HY-L037
-
Differentiation Inducing Compound Library
HY-L038
-
Lipid Compound Library
HY-L043
-
Oxygen Sensing Compound Library
HY-L045
-
Anti-COVID-19 Compound Library
HY-L052
-
FDA Approved & Pharmacopeial Drug Library
HY-L066
-
Angiogenesis-Related Compound Library
HY-L088
-
Mitochondria-Targeted Compound Library
HY-L089
-
Human Metabolite Library
HY-L123
-
Nuclear Receptor Compound Library
HY-L126
-
Non-steroidal Anti-Inflammatory Compound Library
HY-L130
-
Pain-Related Compound Library
HY-L139
-
Off-patent Drug Library
HY-L141
-
Metabolic Enzyme Compound Library
HY-L146
-
Cytokine Inhibitors Library
HY-L161
-
Multi-Target Compound Library
HY-L176
-
Radioprotector Library
HY-L178
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Drug Repurposing Compound Library Plus
HY-L035P
-
FDA-Approved Drug Library Plus
HY-L022P
-
FDA-Approved Drug Library Mini
HY-L022M
-
Bioactive Compound Library
HY-L001
-
Protein Kinase Compound Library
HY-L196
-
Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library
HY-L199
-
High-Throughput Bioactive Compound Library
HY-L205
-
Anti-Rheumatic Arthritis Compound Library
HY-L210
-
Anti-Cancer Approved Drug Library
HY-L213
-
Mass Spectrometry Human Metabolite Library
HY-L215
-
Steroid Hormones Library
HY-L239
Publications Citing Use of MedChemExpress (MCE) Desoximetasone
More
Biological Activity
|
IL-1β |
IL-13 |
IL-6 |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HepG2 | EC50 |
10 μM
Compound: Desoximetasone
|
Activation of rat PXR expressed in human HepG2 cells after 24 hrs by luciferase reporter gene based luminescent analysis
Activation of rat PXR expressed in human HepG2 cells after 24 hrs by luciferase reporter gene based luminescent analysis
|
[PMID: 20966043] |
| HepG2 | EC50 |
31.6 μM
Compound: Desoximetasone
|
Activation of human PXR expressed in human HepG2 (DPX-2) cells assessed as induction of CYP3A4 after 24 hrs by luminescent analysis
Activation of human PXR expressed in human HepG2 (DPX-2) cells assessed as induction of CYP3A4 after 24 hrs by luminescent analysis
|
[PMID: 20966043] |
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Male BALB/c mice aged 8-12 weeks old treated Imiquimod (HY-B0180)[1]
-
Dosage:60 mg (in the form of 0.25% desoximetasone ointment)
-
Administration:Topical application; 6 days
-
Result:Markedly reduced the transepidermal water loss and erythema values.
Exhibited improved clinical and pathological features of the psoriasis severity.
Inhibited the expression of all inflammatory cytokines, such as IL‑23, IL‑1β, IL‑6, TNF‑α and IFN‑γ.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 382-67-2
-
Appearance Solid
-
Molecular Weight 376.46
-
Formula C22H29FO4
-
Color White to off-white
-
SMILES
F[C@@]1([C@]2(C=C3)C)[C@](CCC2=CC3=O)([H])[C@@](C[C@@H](C)[C@@H]4C(CO)=O)([H])[C@]4(C)C[C@@H]1O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
J Am Chem Soc
2021 Nov 10;143(44):18467-18480. PMID: 34648292
Solvent & Solubility
DMSO : ≥ 100 mg/mL (265.63 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
H2O : 0.14 mg/mL (0.37 mM; Need ultrasonic)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (6.64 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (6.64 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (278 KB)
-
SDS (644 KB)
- English - EN (644 KB)
- Français - FR (644 KB)
- Deutsch - DE (644 KB)
- Norwegian - NO (644 KB)
- Español - ES (644 KB)
- Swedish - SV (644 KB)
- Italian - IT (644 KB)
- Korean - KR (644 KB)
- Portuguese - PT (644 KB)
-
Handling Instructions (2659 KB)
References
[1]. Guo JW, et al. Magnolol may contribute to barrier function improvement on imiquimod-induced psoriasis-like dermatitis animal model via the downregulation of interleukin-23. Exp Ther Med. 2021 May;21(5):448. [Content Brief]
[2]. Guo JW, et al. A Promising Approach to Treat Psoriasis: Inhibiting Cytochrome P450 3A4 Metabolism to Enhance Desoximetasone Therapy. Pharmaceutics. 2023 Jul 25;15(8):2016. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.6563 mL | 13.2816 mL | 26.5632 mL | 66.4081 mL |
| 5 mM | 0.5313 mL | 2.6563 mL | 5.3126 mL | 13.2816 mL | |
| 10 mM | 0.2656 mL | 1.3282 mL | 2.6563 mL | 6.6408 mL | |
| 15 mM | 0.1771 mL | 0.8854 mL | 1.7709 mL | 4.4272 mL | |
| 20 mM | 0.1328 mL | 0.6641 mL | 1.3282 mL | 3.3204 mL | |
| 25 mM | 0.1063 mL | 0.5313 mL | 1.0625 mL | 2.6563 mL | |
| 30 mM | 0.0885 mL | 0.4427 mL | 0.8854 mL | 2.2136 mL | |
| 40 mM | 0.0664 mL | 0.3320 mL | 0.6641 mL | 1.6602 mL | |
| 50 mM | 0.0531 mL | 0.2656 mL | 0.5313 mL | 1.3282 mL | |
| 60 mM | 0.0443 mL | 0.2214 mL | 0.4427 mL | 1.1068 mL | |
| 80 mM | 0.0332 mL | 0.1660 mL | 0.3320 mL | 0.8301 mL | |
| 100 mM | 0.0266 mL | 0.1328 mL | 0.2656 mL | 0.6641 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Desoximetasone Related Classifications
HY-17570 Related Classifications
Powered by Bioz